

# **Supplementary Materials**

## **for**

## **The Clinical relevance of Polygenic Risk Scores to Type 2 Diabetes Mellitus in Korean Population**

Na Yeon Kim<sup>1</sup>, Haekyung Lee<sup>2</sup>, Sehee Kim<sup>3</sup>, Ye-Jee Kim<sup>3</sup>, Hyunsuk Lee<sup>4,5</sup>, Junhyeong Lee<sup>1</sup>,  
Soo Heon Kwak<sup>4</sup>, Seunggeun Lee<sup>1,\*</sup>

### **Corresponding author**

Seunggeun Lee


Graduate School of Data Science

Seoul National University, Seoul, South Korea


lee7801@snu.ac.kr

## Supplementary Figures

**Supplementary Fig. S1** Manhattan plot of meta-analysis of East Asian T2DM




**Supplementary Fig. S2** KoGES Ansan and Ansung: Kaplan-Meier curve for cumulative prevalence of T2DM by PRS group



Each shaded area represents 95% confidence band for each curve. Each dash line indicates median age-at-T2DM diagnosis for each PRS group.


**Supplementary Fig. S3** UKBB East Asian validation: Kaplan-Meier curve for cumulative prevalence of T2DM by PRS Group



Each shaded area represents 95% confidence band for each curve.


**Supplementary Fig. S4** Retrograde trajectory of HOMA-IR and HOMA-B. A. Diabetes (HOMA-IR) B. Non-Diabetes (HOMA-IR) C. Diabetes (HOMA-B) D. Non-Diabetes (HOMA-B)

B)



Each bar represents 95% confidence interval at each time point.

**Supplementary Fig. S5** Novel diabetic subgroup characteristics



## Supplementary Tables

**Supplementary Table S1** Area under the receiver operating characteristics curve (AUC) of different methods

	<b>T2DM ~ PRS</b>	<b>T2DM ~ PRS + sex + age</b>
<b>Lassosum</b>	0.64859	0.67599
<b>PRS-CS</b>	0.64766	0.67691

**Supplementary Table S2** Dropout rate of Participants of Koges\_Ansan and Ansung dataset

Follow-up	Baseline	1st	2nd	3rd	4th	5th	6th	7th
<b>Dropout Rate (%)</b>	0	5.14	10.66	15.12	14.48	15.45	17.81	11.57

**Supplementary Table S3** Cumulative prevalence of T2DM for baseline and each follow-up of

Koges\_Ansan and Ansung dataset

<b>Follow-up</b>	<b>Baseline</b>	<b>1st</b>	<b>2nd</b>	<b>3rd</b>	<b>4th</b>	<b>5th</b>	<b>6th</b>	<b>7th</b>
<b>NGT</b>	2572	2539	1821	1351	975	838	711	600
<b>Prediabetes</b>	2172	2015	2544	2832	3043	3039	3048	2995
<b>Diabetes</b>	746	936	1125	1307	1472	1613	1731	1895

**Supplementary Table S4** Results of Cox regression analysis for cumulative prevalence of T2DM by PRS group

<b>PRS</b>	<b>Hazard Ratio</b>	<b>95% CI</b>	<b>P-value</b>
<b>Categorized PRS</b>			
Bottom Decile	0.45	<i>0.36 – 0.56</i>	<i>2.84E-13</i>
Middle (10-90%)	1.00 (reference)		
Top Decile	2.290	<i>12.02 – 2.59</i>	<i>2.00E-16</i>

In the Cox regression model, sex was included as a predictor.

**Supplementary Table S5** Results of Cox regression analysis for predicting T2DM complication

T2DM Complications	PRS	Hazard Ratio	95% CI	P-value
<b>Macrovascular Complications</b>	<b>Categorized PRS</b>			
	Bottom Decile	0.6047	0.2233 – 1.637	0.322
	Middle (10-90%)	1.00 (reference)		
	Top Decile	0.7980	0.5325 – 1.196	0.275
<b>Nephropathy</b>	<b>Standardized PRS</b>	0.9816	0.8415 – 1.145	0.813
	<b>Categorized PRS</b>			
	Bottom Decile	0.9122	0.4675 – 1.780	0.788
	Middle (10-90%)	1.00 (reference)		
	Top Decile	0.8548	0.6197 – 1.179	0.339
	<b>Standardized PRS</b>	0.9177	0.8110 – 1.038	0.173

specified as macrovascular complications and nephropathy

Macrovascular complications include myocardial infarction, coronary artery disease, congestive heart failure, cerebrovascular disease, peripheral artery disease.

**Supplementary Table S6** Characteristics at the baseline of the KoGES\_Ansan and Ansung non-diabetic population dataset

	<b>PRS Bottom Decile (n = 348)</b>	<b>Middle (10-90%) (n = 2075)</b>	<b>PRS Top Decile (n = 149)</b>	<b>P-value</b>
<b>Basic Information</b>				
Male (%)	173 (49.71)	941 (45.35)	66 (44.30)	0.295
Age (year)	50.73 ± 8.24	49.69 ± 8.46	48.61 ± 7.41	0.014
<b>Physical Measurements</b>				
BMI (kg/m <sup>2</sup> )	24.08 ± 2.89	24.10 ± 2.87	24.41 ± 2.80	0.424
SBP (mmHg)	117.62 ± 16.03	117.98 ± 17.07	118.74 ± 18.08	0.796
DBP (mmHg)	79.03 ± 10.74	78.85 ± 11.41	79.03 ± 11.85	0.95
<b>Clinical Risk Factors</b>				
HDL (mg/dL)	50.07 ± 11.75	50.48 ± 11.69	50.01 ± 11.39	0.764
LDL (mg/dL)	115.64 ± 30.30	115.72 ± 31.63	115.55 ± 29.62	0.997
TG (mg/dL)	133.18 ± 81.57	152.93 ± 111.57	126.77 ± 61.24	0.759
Fasting Glucose (mg/dL)	84.29 ± 11.47	131.97 ± 93.41	87.20 ± 7.00	6.06e-05
Fasting Insulin (μIU/mL)	7.05 ± 3.58	7.29 ± 4.76	7.74 ± 7.61	0.348
HbA1C (%)	5.29 ± 0.32	5.34 ± 0.22	5.34 ± 0.22	0.00719
<b>Others</b>				
Current Smoking (%)	89 (25.58)	460 (22.17)	30 (20.13)	0.254
Family History (%)	21 (6.03)	200 (9.64)	15 (10.07)	0.091

BMI: Body Mass Index; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; HDL: High-Density Lipoprotein; LDL: Low-Density Lipoprotein; TG: Triglyceride. Obtained P-value using one-way ANOVA analysis.